Drugs · acquisition-cost intelligence
Hydroxyzine HCL
· ingredient hydroxyzineDiphenylmethane derivatives· HYDROXYZINE DIHYDROCHLORIDE 50 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.05989
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other hydroxyzine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Hydroxyzine Hydrochloride | $0.03562 | −$0.02430 |
| hydroxyzine hydrochloride | $0.04775 | −$0.01210 |
| hydroxyzine pamoate | $0.07399 | +$0.01410 |
| Hydroxyzine Pamoate | $0.08248 | +$0.02260 |
| Hydroxyzine Hydrochloride | $0.12006 | +$0.06020 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 1
Prior auth 55% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.